Nisa Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 11.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 372,594 shares of the company’s stock after acquiring an additional 38,354 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Eli Lilly and were worth $31,467,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Accredited Investors Inc. boosted its holdings in Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares during the period. Oakworth Capital Inc. boosted its holdings in Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares during the period. Sfmg LLC boosted its holdings in Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. boosted its holdings in Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after acquiring an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC boosted its holdings in Eli Lilly and by 0.8% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after acquiring an additional 24 shares during the period. Institutional investors own 76.31% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock valued at $22,041,236 over the last 90 days. 0.20% of the stock is currently owned by company insiders.
Shares of Eli Lilly and Co (NYSE:LLY) traded up $0.60 during midday trading on Friday, hitting $86.99. The company had a trading volume of 2,106,496 shares, compared to its average volume of 3,260,000. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The stock has a market cap of $95,770.00, a PE ratio of 41.42, a P/E/G ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a 1 year low of $74.00 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS. analysts predict that Eli Lilly and Co will post 4.22 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is 99.05%.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with our FREE daily email newsletter.